Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MYCN is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. Additionally we are shipping MYCN Proteins (10) and MYCN Kits (6) and many more products for this protein.
Showing 10 out of 96 products:
Human Monoclonal MYCN Primary Antibody for ChIP, CyTOF - ABIN152254
Tasseva, Cole, Vance: N-Myc and SP regulate phosphatidylserine synthase-1 expression in brain and glial cells. in The Journal of biological chemistry 2011
Show all 3 references for 152254
Mouse (Murine) Polyclonal MYCN Primary Antibody for ICC, IF - ABIN256650
Sjostrom, Finn, Hahn, Rowitch, Kenney: The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. in Developmental cell 2005
Show all 2 references for 256650
Human Polyclonal MYCN Primary Antibody for EIA, WB - ABIN453206
Alvarez-Rodríguez, Pons: Expression of the proneural gene encoding Mash1 suppresses MYCN mitotic activity. in Journal of cell science 2009
Show all 2 references for 453206
Human Polyclonal MYCN Primary Antibody for WB - ABIN391590
Li, Sun, Chen, Squires, Nowroozizadeh, Liang, Huang: p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. in Molecular cancer research : MCR 2015
Cow (Bovine) Polyclonal MYCN Primary Antibody for WB - ABIN2779428
Hansford, Thomas, Keating, Burkhart, Peaston, Norris, Haber, Armati, Weiss, Marshall: Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. in Proceedings of the National Academy of Sciences of the United States of America 2004
Human Polyclonal MYCN Primary Antibody for IF (p), IHC (p) - ABIN760676
Ramraj, Aravindan, Somasundaram, Herman, Natarajan, Aravindan: Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. in Oncotarget 2016
LMO1 (show LMO1 Antibodies) is an important oncogene (show RAB1A Antibodies) that promotes neuroblastoma (show ARHGEF16 Antibodies) initiation, progression, and widespread metastatic dissemination.
our results identify DOT1L (show DOT1L Antibodies) as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma (show ARHGEF16 Antibodies) oncogenesis. Furthermore, they characterize DOT1L (show DOT1L Antibodies) inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma (show ARHGEF16 Antibodies).
CCCTC-binding factor (CTCF (show CTCF Antibodies)) targets the binding sites within MYCN promoter to facilitate its expression in neuroblastoma (show ARHGEF16 Antibodies) (NB) cells.
PAX3 (show PAX3 Antibodies)-FOXO1 (show FOXO1 Antibodies) collaborates with MYCN during early rhabdomyosarcoma (RMS) tumourigenesis to dysregulate proliferation and inhibit myogenic differentiation and cell death.
The findings reveal a PLK1 (show PLK1 Antibodies)-Fbw7 (show FBXW7 Antibodies)-Myc (show MYC Antibodies) signaling circuit that underlies tumorigenesis and validate PLK1 (show PLK1 Antibodies) inhibitors, alone or with Bcl2 (show BCL2 Antibodies) antagonists, as potential effective therapeutics for MYC (show MYC Antibodies)-overexpressing cancers.
Results show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC.
Rac (show AKT1 Antibodies) activity may be an important determinant of metastatic capability in subsets of neuroblastoma (show ARHGEF16 Antibodies) cells lacking MYCN amplification.
MYCN Gene Amplification is associated with Neuroblastoma (show ARHGEF16 Antibodies).
MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK (show ALK Antibodies)) is sufficient to induce neuroblastoma (show ARHGEF16 Antibodies) (NB) in mouse sympathoadrenal cells
MYCN amplification can be heterogeneous between tumor sites, during tumor progression or following treatment, challenging the notion that MYCN copy number does not change for a particular neuroblastoma (show ARHGEF16 Antibodies).
the role of N-myc in mouse lens development, was examined.
Using comparative genomic hybridization, authors found that NCC (show SLC12A3 Antibodies)-derived NBL (show NUMBL Antibodies) tumors in mice acquired copy number gains and losses that are syntenic to those observed in human MYCN-amplified NBL (show NUMBL Antibodies) including 17q gain, 2p gain and loss of 1p36.
a Mycn target gene encoding the miR (show MLXIP Antibodies) cluster miR-17~92, while most retinoblastomas reemerged without clear genetic alterations in either Mycn or known Mycn targets. This Rb/MYCN model recapitulates key genetic driver alterations seen in human retinoblastoma and reveals the emergence of MYCN independence in an initially MYCN-driven tumor.
ALKR1275Q cooperated with MYCN in the development of aggressive NB, possibly by downregulating the expression of ECM (show MMRN1 Antibodies)/BM-associated genes and by conferring malignant potentials to MYCN-expressing cells.
Reuslts show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC.
Thus, this synergistic effect of ZD55-shMYCN in combination with doxorubicin provides a novel therapy strategy for doxorubicin-resistant neuroblastoma (show ARHGEF16 Antibodies), and is a promising approach for further clinical development.
demonstrate a critical link between Myc (show MYC Antibodies)/Mycn gene activity and glycolysis in spermatogonial stem cell self-renewal
Loss of N-myc significantly impairs the Sonic hedgehog (show SHH Antibodies) signaling pathway and disrupts the expression of cell cycle effectors with a significant reduction of Ccnd2 (show CCND2 Antibodies).
Study shows that ground-state embryonic stem cells express low Myc (show MYC Antibodies) levels. Deletion of both c-myc (show MYC Antibodies) and N-myc activity strongly decreases transcription, splicing, and protein synthesis, leading to proliferation arrest; process is reversible and occurs without affecting pluripotency, suggesting that Myc (show MYC Antibodies)-depleted stem cells enter a state of dormancy.
This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.
N-myc proto-oncogene protein
, class E basic helix-loop-helix protein 37
, neuroblastoma MYC oncogene
, neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene
, oncogene NMYC
, v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived
, v-myc myelocytomatosis viral related oncogene, neuroblastoma derived
, Avian myelocytomatosis viral (v-myc) related oncogene neuroblastoma derived (Nmyc)
, Avian myelocytomatosis viral (v-myc) related oncogene, neuroblastoma derived (Nmyc)
, N-myc protein
, neuroblastoma myc-related oncogene 1